Commerzbank Aktiengesellschaft FI Cuts Stake in Eli Lilly and Company $LLY

Commerzbank Aktiengesellschaft FI cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 12.5% in the 1st quarter, Holdings Channel reports. The fund owned 32,580 shares of the company’s stock after selling 4,645 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Eli Lilly and Company were worth $29,966,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Legacy Wealth Managment LLC ID raised its position in shares of Eli Lilly and Company by 13.1% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 112 shares of the company’s stock worth $103,000 after buying an additional 13 shares in the last quarter. Florida Financial Advisors LLC increased its stake in shares of Eli Lilly and Company by 7.6% in the first quarter. Florida Financial Advisors LLC now owns 1,494 shares of the company’s stock worth $1,376,000 after acquiring an additional 105 shares during the last quarter. Swan Global Investments LLC increased its stake in shares of Eli Lilly and Company by 3.6% during the 1st quarter. Swan Global Investments LLC now owns 666 shares of the company’s stock worth $613,000 after purchasing an additional 23 shares during the last quarter. AlTi Global Inc. boosted its stake in shares of Eli Lilly and Company by 29.8% during the 1st quarter. AlTi Global Inc. now owns 4,100 shares of the company’s stock worth $3,771,000 after acquiring an additional 941 shares in the last quarter. Finally, Harbor Advisors LLC grew its holdings in Eli Lilly and Company by 44.4% during the first quarter. Harbor Advisors LLC now owns 1,300 shares of the company’s stock valued at $1,196,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor interest remains strong in Eli Lilly thanks to its leadership in the fast-growing weight-loss and GLP-1 drug market, which continues to support long-term growth expectations.
• Positive Sentiment: Articles highlighting a possible stock split suggest shares trading above $1,000 could make LLY more accessible to retail investors and keep demand elevated.
• Positive Sentiment: Erste Group Bank issued an optimistic earnings estimate for LLY, reinforcing confidence in the company’s strong profit outlook.
• Neutral Sentiment: Coverage describing Eli Lilly as a trending stock shows the name remains heavily watched, which can amplify moves but does not by itself change fundamentals.
• Neutral Sentiment: Several valuation-focused articles argue the stock looks expensive or fully valued after its massive multi-year rally, suggesting expectations are already high.
• Neutral Sentiment: News about Eli Lilly’s $3.8 billion psychedelic-medicine deal and commentary around the ATAI buyout are more about strategic expansion than immediate revenue impact.
• Negative Sentiment: Recent commentary that LLY may be fully valued, stretched, or expensive has likely added to profit-taking pressure after the stock’s strong advance.
• Negative Sentiment: One market recap noted Eli Lilly fell more than the broader market in the latest session, reflecting a weaker short-term trading tone.

Analysts Set New Price Targets

Several analysts recently weighed in on LLY shares. Berenberg Bank increased their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Bank of America raised their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Guggenheim raised their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Citigroup boosted their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,146.90 on Tuesday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The company has a market cap of $1.08 trillion, a P/E ratio of 40.74, a P/E/G ratio of 1.48 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock’s 50-day simple moving average is $1,122.49 and its 200 day simple moving average is $1,036.98.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 55.5% on a year-over-year basis. During the same period last year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 34.55 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.